{"protocolSection": {"identificationModule": {"nctId": "NCT01007149", "orgStudyIdInfo": {"id": "CIGE025AFR05"}, "secondaryIdInfos": [{"id": "2009-010937-38", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma", "officialTitle": "A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of Fc\u03b5RI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy", "acronym": "NATAIR"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-30", "studyFirstSubmitQcDate": "2009-11-02", "studyFirstPostDateStruct": {"date": "2009-11-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-02-20", "resultsFirstSubmitQcDate": "2012-05-07", "resultsFirstPostDateStruct": {"date": "2012-06-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-18", "lastUpdatePostDateStruct": {"date": "2012-07-20", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will assess the change in the expression of Fc\u03b5RI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe persistent asthma, uncontrolled despite optimal therapy."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Severe asthma,", "non-atopic,", "omalizumab"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "BASIC_SCIENCE", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 79, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omalizumab", "type": "EXPERIMENTAL", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.", "interventionNames": ["Drug: omalizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "omalizumab", "description": "Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.", "armGroupLabels": ["Omalizumab"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo was supplied in vials with solution for subcutaneous injection.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in the Expression of Fc\u03b5RI Receptors of Blood Basophils", "description": "Venous blood samples were collected at screening and at Week 16. Flow cytometry analysis determined the Fc\u03b5RI receptors expression of blood basophils (mean fluorescence intensity(MFI)). Relative change in mean fluorescence intensity at the end of study was expressed as a percentage of baseline value.", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Change From Baseline in the Expression of Fc\u03b5RI Receptors of Dendritic Cells", "description": "Venous blood samples were collected at screening and at Week 16. Flow cytometry analysis determined the Fc\u03b5RI receptors expression of dendritic cells (mean fluorescence intensity (MFI)). Relative change in mean fluorescence intensity at the end of study was expressed as a percentage of baseline value.", "timeFrame": "Baseline and 16 weeks"}], "secondaryOutcomes": [{"measure": "Change in Fractional Exhaled Nitric Oxide (FeNO)", "description": "FeNO was measured at baseline, and after 4, 8, 12 and 16 weeks of treatment. Absolute change in FeNO was expressed at each time point versus baseline value.", "timeFrame": "Baseline and 4, 8, 12 and 16 weeks"}, {"measure": "Change From Baseline in Induced Sputum Eosinophil Count", "description": "The induced sputum eosinophil count was measured in a subset of patients in selected centers. Sputum samples were collected at screening and Week 16. Sputum eosinophil count was expressed as a percentage of total nonsquamous cells. Absolute change in sputum eosinophil count was expressed versus baseline value.", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Change From Baseline in Score of the Shortened Version of the Asthma Control Questionnaire (Symptoms Plus Short-acting \u03b22-agonist)", "description": "The shortened version of the asthma control questionnaire (symptoms plus \u03b22-agonist) consists of 6 subscores (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheeze and rescue short-acting \u03b22-agonist use) between 0 and 6 (0 = no impairment; 6 = maximum impairment) and a total score between 0 and 6 (subscores mean value). Absolute change in total score and subscores count was expressed versus baseline value. A decrease in score indicates improvement.", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Change From Baseline in Nasal Symptom Global Score and Individual Components", "description": "Nasal symptom score calculated from six scales assessing the nasal symptom severity (sneezing, runny nose, congestion, itchy nose, postnasal drip and nasal symptoms overall). These six scores were rated on a scale from 1 to 7, with 7 being the worst rating. Absolute changes in these six scores were expressed versus baseline values. A negative change indicates improvement. The range of the global score was from 1 to 7, since this is the mean value of all the subscores.", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Physician and Patient Global Evaluation of Treatment Effectiveness", "description": "The GETE is an assessment of asthma symptoms controlled in response to asthma treatment. The evaluation was performed independently by both investigator and patient using the same 5 point scale. The scale points are: excellent, good, moderate, poor and worsening. A good or excellent response is suggested as a means of defining a patient who has responded to treatment.", "timeFrame": "16 weeks"}, {"measure": "Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to 16 Weeks", "description": "Spirometry was conducted according to internationally accepted standards. At least three maneuvers were performed at each sampling timepoint. The FEV1 recorded was taken from the maneuver obtained from the single best test curve. The best test curve was defined as the spirogram that gave the largest FEV1.", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Number of Patients With at Least One Asthma-related Event Over 16 Weeks", "description": "Asthma-related events were: unscheduled medical visits, emergency room visits and hospitalizations. Details of exacerbations requiring oral or IV corticosteroids were recorded at each visit.", "timeFrame": "16 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nSevere persistent asthma with the following characteristics:\n\n* Uncontrolled according to Global Initiative for Asthma (GINA) 2007 guidelines and at least 2 exacerbations having required systemic corticosteroid and/or at least 1 hospitalization or emergency room visit in the past year.\n* Treated with high-dose inhaled corticosteroid (i.e. \\> 1,000 \u00b5g beclometasone dipropionate equivalent per day) plus inhaled long-acting \u03b22 agonist (with or without maintenance oral corticosteroid).\n* Non-atopic, i.e. negative blood multiallergic testing and negative Aspergillus-specific IgE-radio allergosorbent blood test and negative skin prick tests to a battery of common aeroallergens\n\nExclusion Criteria:\n\n* Current smokers or smoking history stopped for less than 3 years or \\> 10 pack years.\n* Asthma exacerbation during the 4 weeks prior to randomization.\n* Active lung disease other than non-atopic asthma.\n* Patients with an active cancer, a suspicion of cancer or any history of cancer with less than 5 disease free years.\n* Pregnant or nursing (lactating) women.\n* Treatment with omalizumab.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Arnaud de Villeneuve", "country": "France"}, {"facility": "Novartis Investigative Site", "city": "Bethune", "country": "France", "geoPoint": {"lat": 50.53333, "lon": 2.63333}}, {"facility": "Novartis Investigative Site", "city": "Bordeaux", "country": "France", "geoPoint": {"lat": 44.84044, "lon": -0.5805}}, {"facility": "Novartis Investigative Site", "city": "Clamart", "country": "France", "geoPoint": {"lat": 48.80299, "lon": 2.26692}}, {"facility": "Novartis Investigative Site", "city": "Lyon", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Novartis Investigative Site", "city": "Nantes", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Novartis Investigative Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigative Site", "city": "Strasbourg", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Novartis Investigative Site", "city": "Suresnes", "country": "France", "geoPoint": {"lat": 48.87143, "lon": 2.22929}}, {"facility": "Novartis Investigative Site", "city": "Toulouse", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}]}, "referencesModule": {"references": [{"pmid": "23579324", "type": "DERIVED", "citation": "Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C, Devouassoux G, de Blay F, Couderc LJ, Didier A, O'Callaghan DS, Girodet PO, Bourdeix I, Le Gros V, Humbert M. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013 Aug;144(2):411-419. doi: 10.1378/chest.12-1961."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "79 patients were screened. 41 patients received study medication.", "groups": [{"id": "FG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "FG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "21"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "BG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "41"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.0", "spread": "9.67"}, {"groupId": "BG001", "value": "54.6", "spread": "12.78"}, {"groupId": "BG002", "value": "54.8", "spread": "11.23"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in the Expression of Fc\u03b5RI Receptors of Blood Basophils", "description": "Venous blood samples were collected at screening and at Week 16. Flow cytometry analysis determined the Fc\u03b5RI receptors expression of blood basophils (mean fluorescence intensity(MFI)). Relative change in mean fluorescence intensity at the end of study was expressed as a percentage of baseline value.", "populationDescription": "Intent to Treat Fc\u03b5RI analyzable population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment, and who had a valid baseline and post-treatment measurement of Fc\u03b5RI", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change in MFI", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-84.4", "spread": "17.80"}, {"groupId": "OG001", "value": "27.7", "spread": "87.90"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fractional Exhaled Nitric Oxide (FeNO)", "description": "FeNO was measured at baseline, and after 4, 8, 12 and 16 weeks of treatment. Absolute change in FeNO was expressed at each time point versus baseline value.", "populationDescription": "Intent to Treat population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment. During different time points, participants with observations at that time point were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "parts per billion (ppb)", "timeFrame": "Baseline and 4, 8, 12 and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "Week 4 (N = 19, 19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "21.28"}, {"groupId": "OG001", "value": "-5.9", "spread": "29.72"}]}]}, {"title": "Week 8 (N = 18, 20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "spread": "25.48"}, {"groupId": "OG001", "value": "-7.4", "spread": "30.19"}]}]}, {"title": "Week 12 (N = 19, 18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "17.29"}, {"groupId": "OG001", "value": "1.3", "spread": "30.26"}]}]}, {"title": "Week 16 (N = 18, 19)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "18.19"}, {"groupId": "OG001", "value": "0.7", "spread": "17.57"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Induced Sputum Eosinophil Count", "description": "The induced sputum eosinophil count was measured in a subset of patients in selected centers. Sputum samples were collected at screening and Week 16. Sputum eosinophil count was expressed as a percentage of total nonsquamous cells. Absolute change in sputum eosinophil count was expressed versus baseline value.", "populationDescription": "Intent to Treat population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment. Only patients with measurements at both baseline and week 16 were included in this analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of total nonsquamous cells", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.2", "spread": "32.38"}, {"groupId": "OG001", "value": "2.2", "spread": "10.94"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Score of the Shortened Version of the Asthma Control Questionnaire (Symptoms Plus Short-acting \u03b22-agonist)", "description": "The shortened version of the asthma control questionnaire (symptoms plus \u03b22-agonist) consists of 6 subscores (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheeze and rescue short-acting \u03b22-agonist use) between 0 and 6 (0 = no impairment; 6 = maximum impairment) and a total score between 0 and 6 (subscores mean value). Absolute change in total score and subscores count was expressed versus baseline value. A decrease in score indicates improvement.", "populationDescription": "Intent to Treat Population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score units", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Total score", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "0.98"}, {"groupId": "OG001", "value": "-0.5", "spread": "1.43"}]}]}, {"title": "Nighttime waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "1.61"}, {"groupId": "OG001", "value": "-0.8", "spread": "1.69"}]}]}, {"title": "Symptoms on waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "1.32"}, {"groupId": "OG001", "value": "-0.9", "spread": "1.73"}]}]}, {"title": "Activity limitation", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "1.34"}, {"groupId": "OG001", "value": "-0.5", "spread": "1.94"}]}]}, {"title": "Shortness of breath", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "1.29"}, {"groupId": "OG001", "value": "-0.6", "spread": "1.75"}]}]}, {"title": "Wheeze (N = 19, 21)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "1.62"}, {"groupId": "OG001", "value": "-0.3", "spread": "1.79"}]}]}, {"title": "Use of rescue short-acting \u03b22-agonist", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.57"}, {"groupId": "OG001", "value": "0.3", "spread": "1.45"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Nasal Symptom Global Score and Individual Components", "description": "Nasal symptom score calculated from six scales assessing the nasal symptom severity (sneezing, runny nose, congestion, itchy nose, postnasal drip and nasal symptoms overall). These six scores were rated on a scale from 1 to 7, with 7 being the worst rating. Absolute changes in these six scores were expressed versus baseline values. A negative change indicates improvement. The range of the global score was from 1 to 7, since this is the mean value of all the subscores.", "populationDescription": "Intent to Treat Population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score units", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Global score", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "0.74"}, {"groupId": "OG001", "value": "-0.3", "spread": "1.38"}]}]}, {"title": "Sneezing", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "1.10"}, {"groupId": "OG001", "value": "-0.4", "spread": "1.12"}]}]}, {"title": "Runny nose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "1.20"}, {"groupId": "OG001", "value": "-0.6", "spread": "1.83"}]}]}, {"title": "Congestion", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "1.39"}, {"groupId": "OG001", "value": "-0.7", "spread": "2.24"}]}]}, {"title": "Itchy nose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "0.84"}, {"groupId": "OG001", "value": "0.1", "spread": "1.92"}]}]}, {"title": "Postnasal drip", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "1.50"}, {"groupId": "OG001", "value": "0.3", "spread": "1.37"}]}]}, {"title": "Nasal symptoms overall", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "1.44"}, {"groupId": "OG001", "value": "-0.2", "spread": "1.81"}]}]}]}, {"type": "SECONDARY", "title": "Physician and Patient Global Evaluation of Treatment Effectiveness", "description": "The GETE is an assessment of asthma symptoms controlled in response to asthma treatment. The evaluation was performed independently by both investigator and patient using the same 5 point scale. The scale points are: excellent, good, moderate, poor and worsening. A good or excellent response is suggested as a means of defining a patient who has responded to treatment.", "populationDescription": "Intent to Treat Population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Physician's evaluation - Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Physician's evaluation - Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Physician's evaluation - Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Physician's evaluation - Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Physician's evaluation - Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Patient's evaluation - Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Patient's evaluation - Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Patient's evaluation - Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Patient's evaluation - Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Patient's evaluation - Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to 16 Weeks", "description": "Spirometry was conducted according to internationally accepted standards. At least three maneuvers were performed at each sampling timepoint. The FEV1 recorded was taken from the maneuver obtained from the single best test curve. The best test curve was defined as the spirogram that gave the largest FEV1.", "populationDescription": "Intent to Treat Population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "spread": "0.38"}, {"groupId": "OG001", "value": "0.00", "spread": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With at Least One Asthma-related Event Over 16 Weeks", "description": "Asthma-related events were: unscheduled medical visits, emergency room visits and hospitalizations. Details of exacerbations requiring oral or IV corticosteroids were recorded at each visit.", "populationDescription": "Intent to Treat Population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "11"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Expression of Fc\u03b5RI Receptors of Dendritic Cells", "description": "Venous blood samples were collected at screening and at Week 16. Flow cytometry analysis determined the Fc\u03b5RI receptors expression of dendritic cells (mean fluorescence intensity (MFI)). Relative change in mean fluorescence intensity at the end of study was expressed as a percentage of baseline value.", "populationDescription": "Intent to Treat Fc\u03b5RI analyzable population - all randomized patients who received at least one dose of study drug and had at least one post-baseline efficacy assessment, and who had a valid baseline and post-treatment measurement of Fc\u03b5RI", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change in MFI", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight."}, {"id": "OG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-56.7", "spread": "19.74"}, {"groupId": "OG001", "value": "24.8", "spread": "111.71"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Safety population - all patients who received at least one dose of study drug and had at least one post-baseline safety assessment", "eventGroups": [{"id": "EG000", "title": "Omalizumab", "description": "Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.", "seriousNumAffected": 2, "seriousNumAtRisk": 20, "otherNumAffected": 16, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Placebo", "description": "Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 21, "otherNumAffected": 16, "otherNumAtRisk": 21}], "seriousEvents": [{"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}], "otherEvents": [{"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Lip oedema", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Face oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Gait disturbance", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Injection site pruritus", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Acarodermatitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Ear infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 21}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 21}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 21}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 21}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 21}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}